Economic evaluation of Agomelatine (Valdoxan®) for the treatment of major depressive disorder.
|April 2009||03/09/09||Reimbursement not recommended.|
3rd September 2009 – At the current price agomelatine (Valdoxan®) is not considered cost-effective for the treatment of major depressive episodes under the Community Drugs Schemes.
11th December 2009 – Following a revision in price application we now consider agomelatine (Valdoxan®) cost effective under the Community Drugs schemes. The product will now be added to the list of items reimbursable under the schemes.